Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

S Rao, M G Guren, K Khan, G Brown, A G Renehan, S E Steigen, E Deutsch, E Martinelli, D Arnold, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, S Rao, M G Guren, K Khan, G Brown, A G Renehan, S E Steigen, E Deutsch, E Martinelli, D Arnold, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

No abstract available

Keywords: anal cancer; clinical practice guidelines; diagnosis; follow-up; treatment.

Conflict of interest statement

Disclosure DA reports receipt of honoraria for advisory boards, educational activities and/or presentations from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Roche, Sanofi, Servier, Sirtex, Terumo, Art Tempi, PriME Oncology and TRM Oncology; travel support from AstraZeneca, Bristol-Myers Squibb, Roche and Sanofi; research funding to institute from AstraZeneca, Incyte, Merck Sharp & Dohme, Roche and Sanofi; and non-renumerated activities (advisory role and/or principal investigator function) for Mologen and Oncolytics. ED reports grants and personal fees from Roche Genentech and Merck Serono and grants from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb and Merck Sharp & Dohme. EM has served as a speaker for Merck Serono, Servier and Amgen, and as an advisor for Pierre-Fabre, Incyte, Bayer, AstraZeneca, Roche, Sanofi and ESMO. MGG has received institutional research funding from Bristol-Myers Squibb, Incyte and Merck Sharp & Dohme. SR reports receipt of honoraria for advisory boards from Bayer, Roche, Servier, Merck Serono and received travel support from Incyte, Bayer and Servier. KK, GB, AGR and SES have declared no conflicts of interest.